These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 29263030)

  • 1. BET Proteins as Targets for Anticancer Treatment.
    Stathis A; Bertoni F
    Cancer Discov; 2018 Jan; 8(1):24-36. PubMed ID: 29263030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
    Braun T; Gardin C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics.
    Halder TG; Soldi R; Sharma S
    Curr Opin Oncol; 2021 Sep; 33(5):526-531. PubMed ID: 34280171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
    Ramadoss M; Mahadevan V
    Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
    White ME; Fenger JM; Carson WE
    Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
    Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
    Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET inhibitors: a novel epigenetic approach.
    Doroshow DB; Eder JP; LoRusso PM
    Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.
    Wang ZQ; Zhang ZC; Wu YY; Pi YN; Lou SH; Liu TB; Lou G; Yang C
    Signal Transduct Target Ther; 2023 Nov; 8(1):420. PubMed ID: 37926722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical perspectives of BET inhibition in ovarian cancer.
    Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
    Cell Oncol (Dordr); 2021 Apr; 44(2):237-249. PubMed ID: 33469840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
    Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
    Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
    [No Abstract]   [Full Text] [Related]  

  • 18. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.
    Jiménez I; Baruchel A; Doz F; Schulte J
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27900832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET Proteins as Attractive Targets for Cancer Therapeutics.
    Sarnik J; Popławski T; Tokarz P
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Cancer Cells with BET Bromodomain Inhibitors.
    Xu Y; Vakoc CR
    Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 28213432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.